84 related articles for article (PubMed ID: 22339915)
1. [Study of hypermethylation of SOCS gene in typical myeloproliferative disease].
Qin W; Li LL; Lu HN; Huang BB; Xiu B; Bo LJ; Gao QM; Zhang WJ; Fu JF
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):772-6. PubMed ID: 22339915
[TBL] [Abstract][Full Text] [Related]
2. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between socs3 mRNA expression and jak2v617f point mutation in bcr-abl negative patients with myelo-proliferative disease].
Wang DM; Pan L; Zhang JM; Li YH; Wang HF; Wang XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):479-83. PubMed ID: 18549612
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
6. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
[TBL] [Abstract][Full Text] [Related]
7. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
[TBL] [Abstract][Full Text] [Related]
8. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
9. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
[TBL] [Abstract][Full Text] [Related]
10. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
12. Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm.
Zhang MY; Fung TK; Chen FY; Chim CS
J Cell Mol Med; 2013 Oct; 17(10):1282-90. PubMed ID: 24131863
[TBL] [Abstract][Full Text] [Related]
13. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.
Teofili L; Martini M; Cenci T; Guidi F; Torti L; Giona F; Foà R; Leone G; Larocca LM
Int J Cancer; 2008 Oct; 123(7):1586-92. PubMed ID: 18623127
[TBL] [Abstract][Full Text] [Related]
15. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells.
Kim MH; Kim MS; Kim W; Kang MA; Cacalano NA; Kang SB; Shin YJ; Jeong JH
PLoS One; 2015; 10(4):e0123133. PubMed ID: 25849377
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.
Tognon R; Gasparotto EP; Leroy JM; Oliveira GL; Neves RP; Carrara Rde C; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Velano CE; Simões BP; Alberto FL; Miyashiro K; de Souza AM; Amarante-Mendes GP; de Castro FA
J Clin Pathol; 2011 Jan; 64(1):75-82. PubMed ID: 21045235
[TBL] [Abstract][Full Text] [Related]
17. Fully automated and super-rapid system for the detection of JAK2V617F mutation.
Tanaka R; Kuroda J; Stevenson W; Ashihara E; Ishikawa T; Taki T; Kobayashi Y; Kamitsuji Y; Kawata E; Takeuchi M; Murotani Y; Yokota A; Hirai M; Majima S; Taniwaki M; Maekawa T; Kimura S
Leuk Res; 2008 Sep; 32(9):1462-7. PubMed ID: 18328559
[TBL] [Abstract][Full Text] [Related]
18. [Study of single nucleotide polymorphism of SOCS gene in typical myeloproliferative neoplasms].
Qin W; Chen T; Yang JH; Zhang Y; Xiao R; Lu JT; Wang T; Zhou M; He JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1507-12. PubMed ID: 24370038
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients.
Hsiao HH; Liu YC; Yang MY; Tsai YF; Liu TC; Chang CS; Lin SF
Genet Mol Res; 2013 Nov; 12(4):5617-22. PubMed ID: 24301930
[TBL] [Abstract][Full Text] [Related]
20. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Chen CQ; Yu K; Yan QX; Xing CY; Chen Y; Yan Z; Shi YF; Zhao KW; Gao SM
Carcinogenesis; 2013 Jul; 34(7):1442-9. PubMed ID: 23430957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
